Skip to content
Guavy Logo GUAVY
Sign up
Back to Guavy Wire
Crypto

SLS Stock Soars on Leukemia Trial Progress and Research Showing Current Treatments May Fall Short

Guavy AI Editorial Team
Instruments
GAL
Share

SELLAS Life Sciences' (SLS) stock has skyrocketed 255% in 2025, driven by optimism surrounding its Phase 3 REGAL trial results for galinpepimut-S in acute myeloid leukemia patients.

The clinical study has achieved its predetermined 80-event benchmark, allowing the company to initiate comprehensive final analysis.

Recent research published in Haematologica suggests that existing standard therapies may underperform previous expectations, potentially creating an opportunity for SELLAS's candidate.

More on Crypto

Crypto just now

HYPE Blasts Past $83 as Regulatory Optimism and Fee Revenue Drive Price Surge

Crypto just now

BitMart Reconsiders Closure Amid Restructuring Plans

Crypto just now

BitMart Explores Restructuring Amid Growing Customer Backlash

Disclaimer: Guavy is a data and market intelligence provider, not an investment adviser. The information, signals, and market analysis provided by the Guavy API and related services are for informational purposes only and are not intended as financial advice, investment recommendations, or an endorsement of any particular trading strategy. Trading in volatile markets, including cryptocurrency, carries significant risk and may not be suitable for all investors. Past performance is not indicative of future results. Users should consult with a qualified financial professional before making any investment decisions. Guavy makes no guarantee of trading profits or financial returns.

Guavy Logo GUAVY

Market sentiment intelligence for apps, funds & agents

Location

729 55 Ave SW
Calgary AB T2V 0G4
Canada

Navigate

Markets

Resources

© 2026 Guavy Inc

Terms Privacy Policy